A Single Centre, Randomised, Double-blind, Placebo-controlled, Phase Ib Study to Evaluate the Safety, Tolerability and Chemoprotective Antimalarial Activity of P218 Against Controlled Human Malaria Infection With Plasmodium Falciparum Sporozoite Challenge in Non-immune Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs P-218 (Primary) ; Malaria vaccine live unattenuated-Sanaria
- Indications Falciparum malaria; Malaria
- Focus Adverse reactions; Pharmacodynamics
- 29 May 2019 Status changed from recruiting to completed.
- 22 Jan 2019 Status changed from not yet recruiting to recruiting.
- 25 Oct 2018 New trial record